Thrivent Financial for Lutherans Reduces Stake in Exelixis, Inc. (NASDAQ:EXEL)

Thrivent Financial for Lutherans lowered its stake in Exelixis, Inc. (NASDAQ:EXEL – Get Rating) by 32.9% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 85,918 shares of the biotechnology company’s stock after selling 42,036 shares during the period. Thrivent Financial for Lutherans’ holdings in Exelixis were worth $1,378,000 as of its most recent SEC filing.

Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Dimensional Fund Advisors LP grew its position in Exelixis by 6.8% in the third quarter. Dimensional Fund Advisors LP now owns 4,035,449 shares of the biotechnology company’s stock worth $63,279,000 after acquiring an additional 255,886 shares in the last quarter. Trexquant Investment LP grew its position in Exelixis by 33.4% in the third quarter. Trexquant Investment LP now owns 163,738 shares of the biotechnology company’s stock worth $2,567,000 after acquiring an additional 40,958 shares in the last quarter. Brinker Capital Investments LLC grew its position in Exelixis by 5.5% in the fourth quarter. Brinker Capital Investments LLC now owns 146,605 shares of the biotechnology company’s stock worth $2,352,000 after acquiring an additional 7,671 shares in the last quarter. ProShare Advisors LLC grew its position in Exelixis by 3.3% in the fourth quarter. ProShare Advisors LLC now owns 51,440 shares of the biotechnology company’s stock worth $825,000 after acquiring an additional 1,656 shares in the last quarter. Finally, Verition Fund Management LLC grew its position in Exelixis by 187.5% in the third quarter. Verition Fund Management LLC now owns 37,705 shares of the biotechnology company’s stock worth $591,000 after acquiring an additional 24,589 shares in the last quarter. Hedge funds and other institutional investors own 84.74% of the company’s stock.

Wall Street Analysts Forecast Growth

Several research firms recently commented on EXEL. StockNews.com began coverage on Exelixis in a research report on Thursday. They issued a “buy” rating for the company. Wells Fargo & Company began coverage on Exelixis in a research report on Thursday, March 9th. They set an “overweight” rating and a $23.00 target price for the company. Piper Sandler restated an “overweight” rating and set a $32.00 target price on shares of Exelixis in a research report on Wednesday, February 8th. EF Hutton Acquisition Co. I restated a “buy” rating and set a $24.00 target price on shares of Exelixis in a research report on Friday, March 3rd. Finally, Stifel Nicolaus boosted their target price on Exelixis from $20.00 to $21.00 in a research report on Wednesday, May 10th. One analyst has rated the stock with a hold rating and eight have issued a buy rating to the company. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus price target of $25.33.

Insider Activity

In other news, EVP Jeffrey Hessekiel sold 77,860 shares of Exelixis stock in a transaction that occurred on Wednesday, March 1st. The shares were sold at an average price of $17.13, for a total transaction of $1,333,741.80. Following the completion of the sale, the executive vice president now owns 527,716 shares of the company’s stock, valued at $9,039,775.08. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. In related news, Director Jack L. Wyszomierski sold 15,300 shares of the business’s stock in a transaction that occurred on Friday, March 10th. The shares were sold at an average price of $16.61, for a total value of $254,133.00. Following the completion of the transaction, the director now owns 317,467 shares of the company’s stock, valued at $5,273,126.87. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. Also, EVP Jeffrey Hessekiel sold 77,860 shares of the business’s stock in a transaction that occurred on Wednesday, March 1st. The stock was sold at an average price of $17.13, for a total transaction of $1,333,741.80. Following the completion of the transaction, the executive vice president now directly owns 527,716 shares of the company’s stock, valued at approximately $9,039,775.08. The disclosure for this sale can be found here. Over the last quarter, insiders sold 172,100 shares of company stock valued at $3,066,639. Corporate insiders own 2.90% of the company’s stock.

Exelixis Stock Performance

Exelixis stock opened at $19.79 on Monday. The company has a 50 day moving average price of $19.02 and a 200-day moving average price of $17.57. Exelixis, Inc. has a fifty-two week low of $14.87 and a fifty-two week high of $22.47. The company has a market capitalization of $6.44 billion, a PE ratio of 41.23, a P/E/G ratio of 0.83 and a beta of 0.68.

Exelixis Company Profile

(Get Rating)

Exelixis, Inc operates as an oncology company, which focuses on discovering, developing, and commercialization of new medicines for difficult-to-treat cancers. Its products include cabometyx, cometriq, and cotellic. The company was founded by Stelios Papadopoulos on November 15, 1994, and is headquartered in Alameda, CA.